Back to Search
Start Over
Further evidence that antipsychotic medication does not prevent long-term psychosis in higher-risk individuals
- Source :
- European Archives of Psychiatry and Clinical Neuroscience. 272:591-602
- Publication Year :
- 2021
- Publisher :
- Springer Science and Business Media LLC, 2021.
-
Abstract
- Although existing guidelines have discouraged use of antipsychotics for general clinical high-risk (CHR) individuals, it is unclear if antipsychotics can prevent psychosis in higher-risk population. We aimed to study the comparative real-world effectiveness of antipsychotic treatments for preventing psychosis in higher-risk CHR individuals. A total of 300 CHR individuals were identified using the structured interview for prodromal syndromes (SIPS) and followed the participants for 3 years. In total, 228(76.0%) individuals completed baseline assessments using the NAPLS-2 risk calculator (NAPLS-2-RC), and 210(92.1%) completed the follow-up. The sample was further stratified according to risk level. “Higher-risk” was defined based on the NAPLS-2-RC risk score (≥ 20%) and SIPS positive symptom total scores (≥ 10). The main outcome was conversion to psychosis and poor functional outcomes, defined as a global assessment of function (GAF) score lower than 60 at follow-up. In higher-risk CHR individuals, we found no significant difference in the rate of conversion to psychosis or poor functional outcomes between the antipsychotic and no-antipsychotic groups. Low-risk individuals treated with antipsychotic drugs were more likely exhibit poor functional outcomes compared with the no-antipsychotics group(NAPLS-2-RC estimated risk: χ2 = 8.330, p = 0.004; Positive symptom severity: χ2 = 12.997, p
- Subjects :
- Olanzapine
medicine.medical_specialty
Risk level
education.field_of_study
Psychosis
Framingham Risk Score
business.industry
medicine.medical_treatment
Population
General Medicine
medicine.disease
Psychiatry and Mental health
Internal medicine
Structured interview
Medicine
Pharmacology (medical)
Aripiprazole
business
Antipsychotic
education
Biological Psychiatry
medicine.drug
Subjects
Details
- ISSN :
- 14338491 and 09401334
- Volume :
- 272
- Database :
- OpenAIRE
- Journal :
- European Archives of Psychiatry and Clinical Neuroscience
- Accession number :
- edsair.doi...........83628bb276fbc22c7c63a94ad1c1a5c9
- Full Text :
- https://doi.org/10.1007/s00406-021-01331-2